Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study
Consistent with clinical trials, this post-marketing database study observed that newly prescribed iGlarLixi has a low risk of serious hypoglycaemia or hyperglycaemia in Japanese people with T2D, irrespective of prior antidiabetic drug treatment.
Authors
- Hideaki Kaneto (ORCID: https://orcid.org/0000-0001-7898-1943)
- Yoko Takahashi (ORCID: https://orcid.org/0000-0003-2481-9574)
- M. Hatanaka (ORCID: https://orcid.org/0009-0008-2733-8382)
- Yukiko Morimoto (ORCID: https://orcid.org/0000-0001-7751-389X)
- Yasuo Terauchi (ORCID: https://orcid.org/0000-0002-8872-3697)
Institutions
- Kawasaki Medical School (JP)
- Sanofi (Japan) (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-03-08
- DOI
- https://doi.org/10.1007/s12325-025-03135-5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi K.K.